Samsung C&T Confirms Samsung Biologics Rights Issue Price at KRW 1.17 Million a Share

Bitget2026/11/05 10:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Samsung C&T corrected its disclosure on November 5, 2026, confirming Samsung Biologics’ final share issue price at KRW 1.17 million.
The offering comprises 2,270,000 common shares to raise KRW 2.66 trillion for acquiring securities in another company.
The correction also changed the offering’s Fair Trade Commission filing requirement from no to yes.
Existing shareholders can subscribe November 9–10, 2026; payment is due November 17, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung C&T Corporation published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261105800955), on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Samsung C&T Confirms Samsung Biologics Rights Issue Price at KRW 1.17 Million a Share

You may also like

Crypto prices